Ibrance decided for the health insurance benefit while Olita Tab to be decided later after Phase III clinical trial

Published: 2017-11-03 15:36:11

Updated: 2017-11-03 15:36:11

The patient sharing amount for Pfizer Pharmaceuticals Korea’s Ibrance Cap(palbociclib) will be reduced from KRW 5 million to KRW 150 thousand with approval of the national health insurance service(NHIS).

Hanmi Pharm’s Olita Tab(olmutinib) was decided to discuss about its health insurance benefit after a Phase III clinical trial.

The Ministry of Health and Welfare announced to decide the targe...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.